Cargando…
Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution
BACKGROUND: Management of pure intraductal papillomas (IDP) without atypia diagnosed on core needle biopsy (CNB) remains controversial given highly variable rates of upgrade in the literature. AIM: We sought to identify clinical and histologic factors that predict upgrade to atypia or malignancy in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955065/ https://www.ncbi.nlm.nih.gov/pubmed/34729946 http://dx.doi.org/10.1002/cnr2.1481 |
_version_ | 1784676247730651136 |
---|---|
author | Alberty‐Oller, J. Jaime Reyes, Sylvia Moshier, Erin Ru, Meng Weltz, Sarah Santos, Antonio Pisapati, Kereeti Port, Elisa Jaffer, Shabnam |
author_facet | Alberty‐Oller, J. Jaime Reyes, Sylvia Moshier, Erin Ru, Meng Weltz, Sarah Santos, Antonio Pisapati, Kereeti Port, Elisa Jaffer, Shabnam |
author_sort | Alberty‐Oller, J. Jaime |
collection | PubMed |
description | BACKGROUND: Management of pure intraductal papillomas (IDP) without atypia diagnosed on core needle biopsy (CNB) remains controversial given highly variable rates of upgrade in the literature. AIM: We sought to identify clinical and histologic factors that predict upgrade to atypia or malignancy in a large population. METHODS AND RESULTS: A retrospective review was performed of all cases of pure IDP diagnosed on CNB and then surgically excised at a single institution from 2008 to 2018. Clinical, radiologic, and pathologic factors were compared in the no upgrade, upgrade to atypia, or upgrade to cancer groups. Univariate analysis was performed comparing no upgrade and upgrade to cancer or atypia. Four hundred and thirty nine patients were identified with a total of 490 IDP and a median age of 50 years (range 16–85). Of these patients, 54 (12.3%) were upgraded to atypia after surgical excision and five (1.1%) were upgraded to cancer. The presence of multiple papillomas in a single patient was a significant predictor of upgrade to cancer or atypia (p < .01), as well as age over ≥55 years (p < .01) and a prior history of cancer (p < .01). No other clinical, radiologic and histologic factors were found to be significant predictors of upgrade. 40/439 (9.1%) patients in the total cohort had prior history of cancer, and of these, 2/40 (5%) were found to have a new cancer after excision. CONCLUSIONS: In patients with pure IDP on CNB, the upgrade rate to malignancy was 1.1%, while 12.3% were upgraded to atypia. The clinical significance of identifying atypia in a papilloma is unknown, especially in a patient with a prior history of atypia or cancer. However, the majority of patients who were upgraded to either atypia or cancer had no prior history of high‐risk or malignant breast disease and are therefore considered true clinical upgrades. As such excision for IDP should be considered. |
format | Online Article Text |
id | pubmed-8955065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89550652022-03-29 Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution Alberty‐Oller, J. Jaime Reyes, Sylvia Moshier, Erin Ru, Meng Weltz, Sarah Santos, Antonio Pisapati, Kereeti Port, Elisa Jaffer, Shabnam Cancer Rep (Hoboken) Original Articles BACKGROUND: Management of pure intraductal papillomas (IDP) without atypia diagnosed on core needle biopsy (CNB) remains controversial given highly variable rates of upgrade in the literature. AIM: We sought to identify clinical and histologic factors that predict upgrade to atypia or malignancy in a large population. METHODS AND RESULTS: A retrospective review was performed of all cases of pure IDP diagnosed on CNB and then surgically excised at a single institution from 2008 to 2018. Clinical, radiologic, and pathologic factors were compared in the no upgrade, upgrade to atypia, or upgrade to cancer groups. Univariate analysis was performed comparing no upgrade and upgrade to cancer or atypia. Four hundred and thirty nine patients were identified with a total of 490 IDP and a median age of 50 years (range 16–85). Of these patients, 54 (12.3%) were upgraded to atypia after surgical excision and five (1.1%) were upgraded to cancer. The presence of multiple papillomas in a single patient was a significant predictor of upgrade to cancer or atypia (p < .01), as well as age over ≥55 years (p < .01) and a prior history of cancer (p < .01). No other clinical, radiologic and histologic factors were found to be significant predictors of upgrade. 40/439 (9.1%) patients in the total cohort had prior history of cancer, and of these, 2/40 (5%) were found to have a new cancer after excision. CONCLUSIONS: In patients with pure IDP on CNB, the upgrade rate to malignancy was 1.1%, while 12.3% were upgraded to atypia. The clinical significance of identifying atypia in a papilloma is unknown, especially in a patient with a prior history of atypia or cancer. However, the majority of patients who were upgraded to either atypia or cancer had no prior history of high‐risk or malignant breast disease and are therefore considered true clinical upgrades. As such excision for IDP should be considered. John Wiley and Sons Inc. 2021-11-02 /pmc/articles/PMC8955065/ /pubmed/34729946 http://dx.doi.org/10.1002/cnr2.1481 Text en © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Alberty‐Oller, J. Jaime Reyes, Sylvia Moshier, Erin Ru, Meng Weltz, Sarah Santos, Antonio Pisapati, Kereeti Port, Elisa Jaffer, Shabnam Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution |
title | Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution |
title_full | Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution |
title_fullStr | Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution |
title_full_unstemmed | Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution |
title_short | Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution |
title_sort | does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? a study of 490 cases at a single institution |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955065/ https://www.ncbi.nlm.nih.gov/pubmed/34729946 http://dx.doi.org/10.1002/cnr2.1481 |
work_keys_str_mv | AT albertyollerjjaime doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution AT reyessylvia doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution AT moshiererin doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution AT rumeng doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution AT weltzsarah doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution AT santosantonio doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution AT pisapatikereeti doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution AT portelisa doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution AT jaffershabnam doesprevioushistoryofcanceroratypiapredicthistologicupgradeforpureintraductalpapillomasdiagnosedviacorebiopsyastudyof490casesatasingleinstitution |